Finding Alzheimer's Before a Mind Fails

Finding Alzheimer's Before a Mind Fails

Posted By Scarlett Law Group || 22-Jan-2008

For a perfectly healthy woman, Dianne Kerley has had quite a few medical tests in recent years: M.R.I. and PET scans of her brain, two spinal taps and hours of memory and thinking tests.

Ms. Kerley, 52, has spent much of her life in the shadow of an illness that gradually destroys memory, personality and the ability to think, speak and live independently. Her mother, grandmother and a maternal great-aunt all developed Alzheimer's disease. Her mother, 78, is in a nursing home in the advanced stages of dementia, helpless and barely responsive.

"She's in her own private purgatory," Ms. Kerley said.

Ms. Kerley is part of an ambitious new scientific effort to find ways to detect Alzheimer's disease at the earliest possible moment. Although the disease may seem like a calamity that strikes suddenly in old age, scientists now think it begins long before the mind fails.

"Alzheimer's disease may be a chronic condition in which changes begin in midlife or even earlier," said Dr. John C. Morris, director of the Alzheimer's Disease Research Center at Washington University in St. Louis, where Ms. Kerley volunteers for studies.

But currently, the diagnosis is not made until symptoms develop, and by then it may already be too late to rescue the brain. Drugs now in use temporarily ease symptoms for some, but cannot halt the underlying disease.

Many scientists believe the best hope of progress, maybe the only hope, lies in detecting the disease early and devising treatments to stop it before brain damage becomes extensive. Better still, they would like to intervene even sooner, by identifying risk factors and treating people preventively - the same strategy that has markedly lowered death rates from heart disease, stroke and some cancers.

So far, Alzheimer's has been unyielding. But research now under way may start answering major questions about when the disease begins and how best to fight it.

A radioactive dye called PIB (for Pittsburgh Compound B) has made it possible to use PET scans to find deposits of amyloid, an Alzheimer's-related protein, in the brains of live human beings. It may lead to earlier diagnosis, help doctors distinguish Alzheimer's from other forms of dementia and let them monitor the effects of treatment.

Studies with the dye have already found significant deposits in 20 percent to 25 percent of seemingly normal people over 65, suggesting that they may be on the way to Alzheimer's, though only time will tell.

"PIB is about the future of where Alzheimer's disease needs to be," said Dr. William E. Klunk, a co-discoverer of the dye at the Alzheimer's research center at the University of Pittsburgh. "PIB is being used today to help determine whether drugs that are meant to prevent or remove amyloid from the brain are working, so we can find drugs that prevent the underlying pathology of the disease."

Though PIB is experimental now, studies began in November that are intended to lead to government approval for wider use.

Currently, for the most common form of Alzheimer's disease, which occurs after age 65, there is no proven means of early detection, no definitive genetic test. But PIB tests might be ready before new treatments emerge, making it possible to predict who will develop Alzheimer's - without being able to help.

Researchers are also using M.R.I. scans to look for early brain changes, and testing blood and spinal fluid for amyloid and other "biomarkers" to see if they can be used to predict Alzheimer's or find it early.

Studies of families in which multiple members have dementia are helping to sort out the genetic underpinnings of the disease.

Finally, experiments are under way to find out whether drugs and vaccines can remove amyloid from the brain or prevent its buildup, and whether doing so would help patients. The new drugs, unlike the ones now available, have the potential to stop or slow the progress of the disease. At the very least, the drug studies will be the first real test of the leading theory of Alzheimer's, which blames amyloid for setting off a chain of events that ultimately ruin the brain.

Some scientists doubt the amyloid theory, but even a staunch skeptic said the studies were important.

Among the skeptics is Dr. Peter Davies, a professor at Albert Einstein Medical College, who said: "You've got to try. Somebody's going to get this right."

But if the amyloid hypothesis does not hold up, much of Alzheimer's research could wind up back at Square 1.

Answers are urgently needed. Alzheimer's was first recognized 100 years ago, and in all that time science has been completely unable to change the course of the disease. Desperate families spend more than $1 billion a year on drugs approved for Alzheimer's that generally have only small effects, if any, on symptoms. Patients' agitation and hallucinations often drive relatives and nursing homes to resort to additional, powerful drugs approved for other diseases like schizophrenia, drugs that can deepen the oblivion and cause severe side effects like diabetes, stroke and movement disorders.

Alzheimer's is the most common cause of dementia (artery disease, Parkinson's and other brain disorders can also lead to dementia). Five million people in the United States have Alzheimer's, most of them over 65. It is the nation's sixth leading cause of death by disease, killing nearly 66,000 people a year and probably contributing to many more deaths. By 2050, according to the Alzheimer's Association, 11 million to 16 million Americans will have the disease. "Sixteen million is a future we can't countenance," said William H. Thies, the association's vice president for medical and scientific relations. "It will bankrupt our health care system."

The costs are already enormous, $148 billion a year - more than three times the cost of chronic lung disease, even though Alzheimer's kills only half as many people. To a great extent, increases in dementia are the price of progress: more and more people are living long enough to get Alzheimer's, some because they survived heart disease, strokes or cancer. It is a cruel trade-off. The disease is by no means inevitable, but among people 85 and older, about 40 percent develop Alzheimer's and spend their so-called golden years in a thicket of confusion, ultimately becoming incontinent, mute, bedridden or forced to use a wheelchair and completely dependent on others.

"It makes people wonder whether they really want to live that long," Dr. Klunk said.

The potential market for prevention and treatment is enormous, and drug companies are eager to exploit it. If a drug could prevent Alzheimer's or just reduce the risk, as statins like Lipitor do for heart disease, half the population over 55 would probably need to take it, Dr. Thies said.

Blog Home
  • 2015 Litigator Awards Ranked Top 1% Lawyers